Anaptysbio, Inc (ANAB) — 10-Q Filings
All 10-Q filings from Anaptysbio, Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
AnaptysBio Swings to Profit on Soaring Collaboration Revenue
— Nov 4, 2025 Risk: medium
AnaptysBio, Inc. (ANAB) reported a significant financial turnaround for the three months ended September 30, 2025, achieving a net income of $15.113 million, a -
AnaptysBio Q2 Collaboration Revenue Plummets 64%
— Aug 6, 2025 Risk: high
ANAPTYSBIO, INC reported a significant decrease in collaboration revenue for the three and six months ended June 30, 2025. For the three months ended June 30, 2 - 10-Q Filing — May 5, 2025
-
AnaptysBio Revenue Surges to $10.1M in Q3 2024
— Nov 5, 2024 Risk: medium
AnaptysBio, Inc. reported its financial results for the quarter ended September 30, 2024. The company's revenue for the nine months ended September 30, 2024, wa -
AnaptysBio Q2 Results: $385M Cash, $1M Revenue, $33M Net Loss
— Aug 5, 2024 Risk: medium
AnaptysBio, Inc. reported its financial results for the second quarter ended June 30, 2024. The company had cash, cash equivalents, and marketable securities of -
AnaptysBio, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: low
ANAPTYSBIO, INC (ANAB) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. AnaptysBio, Inc. filed a 10-Q report for the period ending March 31, 2024. T
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX